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Recurrent axon collaterals are a major means of communication
between spiny projection neurons (SPNs) in the striatum and
profoundly affect the function of the basal ganglia. However,
little is known about the molecular and cellular mechanisms that
underlie this communication. We show that intrastriatal nitric
oxide (NO) signaling elevates the expression of the vesicular GABA
transporter (VGAT) within recurrent collaterals of SPNs. Down-
regulation of striatal NO signaling resulted in an attenuation of
GABAergic signaling in SPN local collaterals, down-regulation of
VGAT expression in local processes of SPNs, and impaired motor
behavior. PKG1 and cAMP response element-binding protein are
involved in the signal transduction that transcriptionally regulates
VGAT by NO. These data suggest that transcriptional control of the
vesicular GABA transporter by NO regulates GABA transmission
and action selection.
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Throughout the CNS, the volume transmitter nitric oxide(NO) has been implicated in modulating synaptic function,
including transmitter release and plasticity (1, 2). The primary
target of NO is soluble guanylyl cyclase (sGC), a heterodimer
comprising α and β subunits. Upon activation, sGC generates
the intracellular messenger cGMP, which, in turn, regulates
downstream targets, including channels, phosphodiesterases,
and kinases, to alter synaptic function (3). Although sGC is
expressed in many adult brain areas, its expression level and
activity are highest in the striatum (4, 5), where it is thought to
facilitate NO-mediated transmission and plasticity at corti-
costriatal synapses (6, 7).
To identify plasticity-related molecules that are regulated by
NO signaling in striatal neurons, we generated striatal-specific
sGCβ1 knockdown (KD) mice and analyzed the resulting tran-
scriptional alterations in a defined population of spiny projection
neurons (SPNs). We demonstrated reduction in the levels of the
vesicular GABA transporter (VGAT) and GABA signaling at
recurrent axon collaterals of striatal SPNs. Signaling between
SPNs was also attenuated by pharmacological inhibition of NO
signaling. The transcriptional regulation of VGAT by cGMP
involved phosphorylation of cAMP response element-binding
protein (CREB) by cGMP-dependent protein kinase G (PKG).
Our data indicate that NO signaling modulates neurotransmis-
sion at neural circuits by modulating the transcription of the
vesicular GABA transporter.
Results
Biochemical and Behavioral Characterization of Striatal-sGCβ1 KD
Mice. We generated striatal sGCβ1 KD mice to identify the cel-
lular processes regulated by NO specifically in striatal neurons of
the adult brain, while avoiding its roles in glutamate nerve ter-
minals, nonneuronal cells, or during neuronal development. For
this siGucy, shRNA against Gucy1b3 (the gene encoding sGCβ1)
was inserted into an AAV2-delivery system, and its activity was
first evaluated in cortical neuron culture. AAV.siGucy or control
AAV (AAV.siLuc) were transduced into 87.1 ± 2.13% and 89.7 ±
1.84% of the neurons in the culture, respectively. AAV.siGucy,
but not AAV.siLuc, reduced endogenous sGCβ1 levels by 44 ±
12% (Fig. 1 A and B) and attenuated NO-induced production of
cGMP by 95 ± 2% (Fig. 1C). Stereotaxic delivery of the virus into
the dorsal striatum of adult mice resulted in specific localiza-
tion of GFP throughout the entire striatum (Fig. 1D), but not
the cortex, indicating that corticostriatal neurons were not
targeted by the virus. In striata transduced with either AAV.
siGucy or AAV.siLuc, over 90% of the GFP-labeled cells were
also positive for the 32-kDa dopamine- and cyclic AMP-regu-
lated phosphoprotein (DARPP-32), suggesting that SPNs are the
primary target of these viruses (Fig. S1). Notably, AAV.siGucy
delivery resulted in a 37 ± 7% reduction of striatal sGCβ1 level
(Fig. 1 E and F). In line with this result, we found that sGC
activity was dramatically reduced in sGCβ1 KD mice, as reflected
by an 82 ± 8% reduction in endogenous striatal cGMP level (Fig.
1G). Interestingly, cAMP levels were not changed in either cul-
tured neurons transduced with AAV.siGucy or in sGCβ1 KD
mice, suggesting that its hydrolysis in the striatum is not regu-
lated by cGMP (Fig. 1 C and G).
Basal motor behavior of sGCβ1 KD mice was evaluated using
the open-field test. sGCβ1 KD mice had higher motor activity
relative to control (Fig. 1H). The induction of motor behavior in
sGC-KD mice was not detected in the first 5 min of the test
(sGCβ1 KD vehicle 714 ± 76 cm; control 621 ± 95 cm; P = 0.12)
(Fig. 1I) whereas acute administration of the nitric oxide syn-
thase inhibitor L-NG-nitroarginine methyl ester, (L-NAME) to
sGCβ1 KD mice attenuated movement (90 ± 20 cm) as pre-
viously shown in WT (8, 9), suggesting that extrastriatal NOS are
Significance
The function of the basal ganglia relies on striatal spiny pro-
jecting neurons (SPNs). Axon collaterals of these GABAergic
neurons form connections with other SPNs as a means of a
feedback inhibition circuit. The mechanisms that regulate neuro-
transmission at these local synapses remain poorly understood. In
this paper, neurotransmission at SPN collaterals is found to be
regulated by the gaseous neurotransmitter nitric oxide, which
activates a signal-transduction cascade that transcriptionally reg-
ulates vesicular GABA transporter specifically at axon collaterals.
These findings illustrate a previously unidentified role for nitric
oxide in striatal learning and action selection.
Author contributions: Y.S., M.H., J.D.P., D.J.S., and P.G. designed research; Y.S. and J.D.P.
performed research; S.M., M.G.K., and N.H. contributed new reagents/analytic tools; Y.S.
and J.D.P. analyzed data; Y.S., M.H., J.D.P., D.J.S., and P.G. wrote the paper; and M.G.K.
provided tools and guidance on methods used in this work.
The authors declare no conflict of interest.
1To whom correspondence may be addressed. Email: greengard@rockefeller.edu or
ysagi@rockefeller.edu.
2Present address: Department of Brain and Cognitive Sciences and Picower Institute for
Learning and Memory, Massachusetts Institute of Technology and Broad Institute of MIT
and Harvard, Cambridge, MA 02139.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1420162111/-/DCSupplemental.
17636–17641 | PNAS | December 9, 2014 | vol. 111 | no. 49 www.pnas.org/cgi/doi/10.1073/pnas.1420162111
the target of the drug. Taken together, these results suggest that
striatal NO signaling regulates motor function.
Striatal VGAT Is Down-Regulated in SPNs of sGCβ1 KD Mice. Accu-
mulating data indicate that striatal NO signaling regulates
synaptic plasticity (6, 7). We therefore hypothesized that the
behavioral impairments in sGCβ1 KD mice are mediated by al-
tering expression of proteins related to plasticity. To identify the
genes regulated by NO signaling, we analyzed the translated
mRNA expression profile of SPNs from sGCβ1 KD mice. To this
end, we used the newly developed translating ribosome affinity
purification (TRAP) system (10, 11) and isolated translated
mRNA from SPNs of the direct projection pathway (dSPNs).
qPCR analysis corroborated a 41 ± 18% reduction in sGCβ1
mRNA in Drd1-expressing SPNs of sGCβ1 KD mice, confirming
that SPNs are the target of the AAV (Fig. 2A). We next com-
pared the expression level of ∼14,000 genes from dSPNs of
sGCβ1 KD-Drd1-TRAP mice to that from mice injected with the
control virus. Of the probe sets, 2.7% were down-regulated in
dSPNs of sGCβ1 KD mice and 7.5% were induced, compared
with control, but none of these genes are associated with gluta-
matergic signaling. In contrast, among the genes showing the
most prominent change was the vesicular GABA transporter
(VGAT, Slc32a1), which was reduced by 38 ± 6% in sGCβ1 KD
relative to control (Table S1). Of all annotated synaptic vesicle-
related genes, 13.5% were differentially regulated in SPNs of
sGCβ1 KD, including stx3, stx7, dept7, syt12, rab9b, kif2a, kif2c,
kif3b, kif3c, kif5b, kif13a, kif17, kif21a, stxbp1, pi3kr1, pi3kc1,
vamp4, and vamp7 (Table S1). However, none of these genes are
functionally related to VGAT, suggesting that the transcriptional
regulation of VGAT by NO signaling is selective and not part of
a complete reorganization in the synaptic vesicle-related pro-
teins. qPCR analysis corroborated a 43 ± 15% reduction in
VGAT-translated mRNA in dSPN of sGCβ1 KD mice (Fig. 2A).
NO signaling has been implicated in modulating the function
of local synapses of SPNs as well as primary projections of dSPNs
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Fig. 1. Biochemical and behavioral impairments in striatal-sGCβ1 KD mice.
(A) Representative Western blot images depicting endogenous sGCβ1,
transduced GFP, and β-actin levels in cortical culture neurons untreated (n =
3 wells) or transduced with either AAV.siGucy (n = 3 wells) or the control
virus, AAV.siLuc (n = 3 wells). (B) Bar graph summary of the data presented
in A. Bars represent mean sGCβ1 levels normalized to β-actin ± SD. (C) Effect
of the nitric oxide donor, diethylamine NONOate (DEA, 10 nM) and a phos-
phodiesterase inhibitor, pentoxifylline (PXF, 150 μM) on cGMP and cAMP
levels in neuron culture (n = 3 for each condition, ***P < 0.001). Bars rep-
resent means ± SD. (D) Representative grayscale immunofluorescent images
of GFP localization after intrastriatal injection of AAV.siGucy, showing GFP
expression in the dorsal striatum (arrow, Left). Magnified images (Middle
and Right) show the somatic GFP labeling throughout the striatum. (Scale
bars: Left, 2 mm, objective 10×;Middle and Right, 200 μm, objective 40×.) (E)
Representative Western blot image of protein level from lysates of the
entire striata after bilateral intrastriatal injections of either AAV.siGucy
or control AAV (AAV.siLuc, n = 4 mice per group, for coordinates see SI
Materials and Methods). (F) Quantification of the data presented in E, in-
dicating a persistent reduction in sGCβ1 level by AAV.siGucy (*P < 0.05). Bars
represent mean densities of sGCβ1 normalized to β-actin ± SD. (G) Quanti-
fication of cGMP and cAMP levels in control or sGCβ1 KD (n = 6 mice per
group, ***P = 0.0004). Bars represent levels normalized to tissue wet
weight ± SD. (H) Spontaneous motor behavior was recorded for 60 min after
vehicle injection. Traveled distance and rest times are illustrated by the open
and closed boxes, respectively (n = 6 mice per group, *P < 0.05). (I) Five-
minute motor activity in sGCβ1 KD mice was compared with that of mice
injected with the nitric synthase inhibitor L-NG-nitroarginine methyl ester
(L-NAME) (n = 6 mice per group, *P < 0.05 vs. untreated control).
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Fig. 2. VGAT is down-regulated in local processes of striatal SPNs in sGCβ1
KD mice. (A) Bar graph summary of mRNA levels of sGCβ1 (gucy1b3), VGAT
(Slc32a1), synaptophysin (Syp), and α-synuclein (Snca) from control Drd1-
TRAP mice and sGCβ1 KD Drd1-TRAP mice (n = 3 per group, **P < 0.01 vs.
control). Bars represent mean mRNA levels normalized to GAPDH, as per-
centage of control ± SD. (B) Colocalization of VGAT and DARPP-32 in the
striatum and substantia nigra pars reticulata (SNr). Representative images
from control (n = 5 mice), showing that VGAT is colocalized with DARPP-32
in the striatum. Note in the magnified images that VGAT is expressed in the
soma (adjacent to the nucleus in blue) but more prominently in processes
(arrows) of SPNs. In sGCβ1 KD (n = 5 mice), VGAT labeling is mainly reduced
in processes but it is still visible in somas (arrows). In control mice, SPNs’
principal projections to the SNr express VGAT, and the labeling of VGAT in
the principal projection remains unchanged in sGCβ1 KDmice. (Scale bar: 20 μm.)
(C) Mean pixel values were determined concomitantly for DARPP-32 and VGAT
in control (n = 5 mice) and sGCβ1 KD mice (n = 5 mice). Analysis of the ratios
indicates that VGAT level is reduced in the striatum of sGCβ1 KD mice (**P =
0.0095). Bars represent mean ratios of mean pixel values ± SEM.
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to the substantia nigra pars reticulata (SNr) (6, 12). To analyze
the cellular localization of VGAT in SPNs of sGCβ1 KD mice,
brain sections were costained for VGAT and DARPP-32. In the
striatum, VGAT was highly but not completely localized in SPNs
(Fig. 2B), with a more prominent localization to neuropil, rela-
tive to perikarya, indicating its presence in recurrent axon col-
laterals. Consistent with the reduction in mRNA level, VGAT-
protein labeling was 55 ± 15% in the striatum of sGCβ1 KD
relative to control mice (Fig. 2 B and C). We next compared the
level of VGAT in dSPNs and indirect projection SPNs (iSPNs),
by analyzing VGAT and GFP immunolabeling in sGCβ1 KD-
Drd1-TRAP mice. In line with the TRAP data, the VGAT level
in Drd1-positive cells of sGCβ1 KD mice was reduced by 32 ±
5.3% and in Drd1-negative neurons by 25 ± 8.5%, relative to
their respective controls (Fig. S2). In contrast to the reduction in
the immunolabeling of VGAT in SPNs, VGAT labeling in
interneurons of these mice was unchanged (Fig. S3), suggesting
that NO signaling regulates VGAT expression in both dSPNs
and iSPNs.
GABA Transmission at Recurrent Collaterals of SPNs Is Impaired in
sGCβ1 KD Mice. To evaluate the role of sGC on GABA trans-
mission in SPNs, GABA miniature inhibitory postsynaptic cur-
rents (mIPSCs) were recorded in SPNs. GABA mIPSC
frequency was 25 ± 8% lower in SPNs taken from sGCβ1 KD
mice compared with controls (Fig. 3 B and C), suggesting a de-
crease in the release probability of GABAergic synapses onto
SPNs (13). Visual inspection of representative records suggested
that the frequency of small-amplitude mIPSCs was selectively
decreased in SPNs of sGCβ1 KD mice (Fig. 3A). This finding was
confirmed by a quantitative analysis of the amplitude distribution
of mIPSCs from equal-length records (Fig. 3D). The distribution
analysis revealed a 29 ± 8% reduction in the number of mIPSCs
with amplitudes less than 65 pA, but not mIPSCs with ampli-
tudes greater than 65 pA (Fig. 3E). The alterations in frequency
and amplitude were not accompanied by a significant change in
mIPSC kinetics (Fig. 3 F and G), suggesting that GABAergic
synapses were not being redistributed. GABAergic synapses onto
SPNs are derived from one of three sources: fast-spiking (FS)
interneurons, neuronal nitric oxide synthase (nNOS)-positive
interneurons, and collateral SPN synapses (14, 15). FS inter-
neurons make perisomatic synapses that give rise to large-
amplitude IPSCs. In contrast, nNOS interneurons and SPN synapse
primarily upon dendrites and give rise to small-amplitude IPSCs.
Because SPNs far outnumber nNOS interneurons, it seems likely
that the drop in the frequency of small-amplitude mIPSCs in
sGCβ1 KD mice is attributable to a reduction in GABA release
from recurrent collaterals.
To physiologically evaluate the function of VGAT in the
efferents of dSPNs of sGCβ1 KD mice, the paired pulse ratio of
IPSCs in SNr neurons was studied. Striatonigral IPSCs were
strongly facilitated and were not altered in sGCβ1 KD mice (Fig.
S4), suggesting that GABA transmission at extrastriatal termi-
nals of SPNs was unchanged.
To determine whether NO signaling directly modulates re-
current collateral synapses, recurrent collaterals of the indirect
pathway were activated optogenetically while recording from
a dSPN, (Fig. 4 A and B). The IPSCs evoked by collateral acti-
vation were significantly diminished by disruption of NOS sig-
naling with L-NAME (100 μM) (Fig. 4 C and D). This result
demonstrates that NO signaling potentiates recurrent collateral
GABAergic synaptic function, in agreement with the inference
drawn from the mIPSC analysis.
PKG1 and CREB Mediate the Transcriptional Regulation of VGAT by
NO. To elucidate the signaling pathway involved in the tran-
scriptional regulation of VGAT by NO, the phosphorylation
level of phosphoproteins involved in striatal and NO signaling,
including DARPP-32, ERK1/2, and CREB (6, 16, 17), was
assessed. In the striatum, the phosphorylation level of serine 133-
CREB was reduced by 62 ± 19% in sGCβ1 KD mice compared
with control mice (Fig. 5 A and B), supporting the idea that
CREB plays a role in the transcriptional regulation of VGAT by
NO. In contrast to CREB, the phosphorylation levels of threo-
nine 202/tyrosine 204-ERK1/2, and threonine 34-DARPP-32 of
sGCβ1 KD mice were 118 ± 9% and 94 ± 13% of the respective
control (Fig. 5 A and B). We next studied whether CREB
phosphorylation is dependent on cGMP and cGMP-dependent
kinase (PKG)1 in striatal slices. We found a 150 ± 22% increase
in CREB phosphorylation after cGMP bath application (Fig. 5 C
and D). PKG1 has an established role in directly phosphorylating
CREB, and this activity may depend on nuclear shuttling of
PKG1 (18). In line with this result, the effect of cGMP was
completely abolished by PKG1 inhibition (106 ± 15% of basal
phosphorylation level) (Fig. 5 C and D). To identify the sub-
cellular localization of PKG1 after activation by cGMP, the cy-
toplasmic and nuclear protein fractions were separated. At basal
level, PKG1 was localized to both nuclear and cytoplasmic
compartments of striatal cells, and cGMP-induced phosphory-
lation of CREB by PKG1 was not associated with changes in
A
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Fig. 3. Decreased frequency of small-amplitude GABAergic currents in
striatal SPNs of sCGβ1 KD mice. (A) Representative spontaneous mIPSC traces
from SPNs of control (n = 18 mice) and sGCβ1 KD (n = 19 mice). (B) Cumu-
lative probability plot summary of mIPSC interevent interval (IEI) from con-
trol or sGCβ1 KD, showing an increase in IEI in SPNs of sGCβ1 KD mice. (C) Bar
graph summary of mIPSC frequency in SPNs from control (n = 18 mice) or
sGCβ1 KD (n = 19 mice), showing a decrease in SPN mIPSCs frequency in
sGCβ1 KD animals (*P = 0.022). Bars represent mean frequency ± SEM. (D,
Lower) Amplitude histogram of mIPSCs in SPNs of control (n = 18 mice) and
sGCβ1 KD (n = 19 mice) showing a decrease in the number of mIPSCs in the
smaller amplitude event bins in sGCβ1 KD mice. (Upper) Cumulative plot of
the difference between control (n = 18 mice) and sGCβ1 KD (n = 19 mice) in
each 10-pA-amplitude bin, showing that the greatest difference between
the groups occurs in the smaller amplitude bins. (E) Bar graph summary of
small (<65 pA) and big (>65 pA) amplitude mIPSCs in equal-length records
(7 min) from control (n = 18 mice) or sGCβ1 KD (n = 19 mice), showing
a decrease in the number of small-amplitude mIPSCs in SPNs of sGCβ1 KD
(**P = 0.006). Bars represent mean counts ± SEM. (F) Bar graph summary of
mean 10–90% rise times (P = 0.524, control, 0.86 ± 0.02, n = 19; sGCβ1 KD,
0.84 ± 0.02, n = 18). (G) Mean decay times (P = 0.664, control, 17.1 ± 1.0, n =
19; sGCβ1 KD, 17.6 ± 0.5, n = 18).
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nuclear or cytoplasmic levels of PKG1 (Fig. 5 E and F), sug-
gesting that the activity of PKG1 in the nucleus is not dependent
on its nuclear shuttling. In sGCβ1 KD mice, the level of PKG1
was reduced in the nucleus (70 ± 6% of control) and the cyto-
plasm (74 ± 10% of control) (Fig. S5), supporting the idea that
the activity of PKG1 in the nucleus may play a role in the
transcriptional regulation by NO.
Finally, to study a direct interaction between CREB and reg-
ulatory elements in the VGAT gene, the sequence of the VGAT
gene (Slc32a1) was analyzed, and a conserved cAMP response
element (CRE) was identified in its intron (Fig. S5). To evaluate
the functionality of this putative CRE, the binding of VGAT to
CREB was studied in vitro. A specific interaction was identified
between phospho-CREB and the vgat gene (Fig. S5). Moreover,
this interaction was dependent on the CRE-like sequence, sug-
gesting that it is functional. To evaluate a possible interaction
between vgat and phospho-CREB in vivo, chromatin from either
the striatum or hippocampus was isolated, and levels of the gene
bound to either phospho-CREB or RNA polymerase II were
assessed using chromatin immunoprecipitation (i.p.) and qPCR.
The levels of vgat precipitated by RNA Polymerase were 4 ±
1.0% and 1.2 ± 0.2% of the striatal and hippocampal gene
inputs, respectively (P = 0.04 between brain areas), and the re-
spective levels precipitated by phospho-CREB were 0.3 ± 0.07%
and 0.08 ± 0.01%, respectively (P = 0.02 between brain areas),
suggesting that CREB plays a role in the transcriptional regulation
of VGAT in striatal neurons. Importantly, in striata of sGCβ1 KD
mice, the binding of vgat by phospho-CREB was reduced by 56 ±
8.7% (Fig. 5G), indicating that CREB-induced transcriptional
regulation of vgat is attenuated in sGCβ1 KD mice.
Dopamine Signaling Regulates Striatal cGMP and Collateral VGAT
Levels in a Coordinated Manner. Striatal dopamine depletion is
associated with impairments in both striatal NO signaling and
GABAergic transmission in axon collaterals of SPNs (14, 19). To
study the role of dopamine in the regulation of striatal NO sig-
naling and VGAT levels in SPNs, cGMP levels or VGAT la-
beling was measured in the striata from 6-hydroxydopamine
lesioned mice (Fig. 6A). Dopaminergic denervation resulted in
a 21 ± 6% reduction in VGAT labeling from the striatum ipsi-
lateral to the lesion (Fig. 6 B and C). The reduction in VGAT
level was observed both in the neuropil and somas of SPNs. In
contrast to the reduction at local processes of SPNs, the level of
VGAT at extrastriatal projections to the globus pallidus and
substantia nigra was not affected by the lesion (Fig. S6), in-
dicating that dopamine transmission modulates VGAT levels
only at recurrent axon collaterals but not at primary projections
of SPNs. Chronic L-dopa treatment increased striatal VGAT
labeling by 37 ± 12% whereas discontinuation of L-dopa resulted
in a 33 ± 11% reduction in the transporter level.
Dopamine depletion also resulted in a 53 ± 5% reduction in
cGMP levels in the striatum ipsilateral to the lesion (ipsilateral
2.2 ± 0.5 pmol/mg wet weight; contralateral 4.5 ± 0.7 pmol/mg
wet weight) (Fig. 6D). Chronic L-dopa treatment increased
cGMP levels by 46 ± 11% (5.4 ± 0.9 pmol/mg wet weight; 3.7 ±
0.5 pmol/mg wet weight) whereas its withdrawal resulted in a 49 ±
14 pmol/mg wet weight loss in cGMP levels (2.0 ± 0.5 pmol/mg
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Fig. 5. Transcriptional regulation of VGAT by NO signaling. (A) Represen-
tative immunoblot image of phosphoproteins from control (n = 4 mice) and
sGCβ1 KD (n = 4 mice). (B) Quantification of the data presented in A, in-
dicating a reduction in phospho-CREB levels in the striata of sGCβ1 KD mice
(**P = 0.006). Bars represent means of phosphorylated fraction ± SD. (C and
D) Effect of cGMP on subcellular levels of PKG1 in striatal slices. (C) Repre-
sentative Western blot images of Ser-133 phospho-CREB and total CREB
levels, after incubation of striatal slices with 8 Br-cGMP (cGMP analog, 5 μM),
RP-cGMPS (PKG1α selective inhibitor, 1 μM, n = 6 slices per group). (D)
Quantification of the data presented in C, showing induction in CREB-
phosphorylation by 8 Br-cGMP alone but not with RP-cGMPS (*P < 0.05 vs.
8 Br-cGMP/RP-cGMPS). Bars represent means of fold change in phosphory-
lated fraction relative to time 0 ± SD. (E) Representative Western blot image
depicting protein subcellular levels after 30 min incubation of striatal slices
with 8 Br-cGMP. (F) Bar graph summary of the data presented in E, in-
dicating that the induction of CREB phosphorylation by 8 Br-cGMP is not
associated with nuclear translocation of PKG1 (5 μM, n = 3 mice, six slices
from each, per group). (G) Impaired interaction between CREB and vgat
gene in sGCβ1 KD mice. Bar graph summary of the striatal levels of vgat
(slc32a1), bound by either S133-phospho-CREB or RNA polymerase II. The level
of bound genes from control (n = 10) or sGCβ1 KD (n = 10) was analyzed using
qPCR. Bars represent mean levels of the immunoprecipitated gene in sGCβ1 KD
mice normalized to input, as percentage of control ± SD (*P < 0.05).
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wet weight; 3.9 ± 1.0 pmol/mg wet weight). Finally, a correlation
between the regulation of cGMP and VGAT levels by dopamine
was evaluated by plotting striatal cGMP level changes against that
of local VGAT labeling. High correlation was identified between
the two (R2 = 0.903) (Fig. 6E), further supporting the idea that
striatal NO mediates the dynamic regulation of axon collateral
function in SPNs by dopaminergic signaling.
Discussion
NO signaling has an established role in mediating plasticity and
transmission in excitatory synapses, including a role in striatal
plasticity at corticostriatal synapses, where it facilitates the re-
sponse of SPNs to glutamate (6, 7). We have previously found
that the NO-sGC-cGMP pathway regulates striatal glutamate
signaling through NMDA/AMPA/mGluR5 receptor activation.
To identify the molecular mechanisms underlying the role of NO
in SPNs, we have used the novel BacTRAP technology. We
demonstrated that a loss of NO signaling from striatal neurons of
the adult mouse striatum results in a specific reduction in the
translated mRNA level of synaptic vesicle-related genes and an
impaired GABAergic transmission at recurrent axon collaterals
of striatal SPNs. By using a striatal-specific sGCβ1 KD strategy,
we have found that transcriptional regulation of VGAT is a
major target of NO-sGC signaling, establishing a mechanism by
which this signaling pathway can trigger synaptic transmission at
GABAergic local synapses. Importantly, we found that SPNs of
the two projection pathways, namely the direct and the indirect
pathways, are both targets of striatal NO signaling. sGCβ1 mRNA
was reduced in dSPN by a similar level to that of the entire
striatal tissue, suggesting that the effect is similar in iSPNs.
Furthermore, immunolabeling of VGAT was reduced by a simi-
lar ratio in both populations in sGCβ1-KD.
Interestingly, sGCβ1-KD mice manifested induction in motor
behavior, highlighting asymmetry in the role of NO on local
communication between the projection systems. This result
suggests that iSPN neurons are more sensitive to the transcrip-
tional regulation of VGAT by NO than dSPNs. In line with this
idea, we and others have previously found that axon collaterals
between SPNs of the two projection systems are not symmet-
rical because iSPNs profoundly innervate and efficiently inhibit
dSPNs (14, 20, 21). Together with these studies, our experiments
suggest that NO signaling regulates motor behavior and action
selection by maintaining the normal function of axon collaterals.
We found that cGMP, sGC, PKG1, and CREB are involved in
the signaling pathway that transcriptionally regulates VGAT by
NO. PKG1 is localized both to the cytoplasm and to the nucleus,
and its nuclear levels are reduced in sGCβ1 KD mice, suggesting
that PKG1 directly regulates the transcription of downstream
genes by phosphorylating nuclear targets, including transcription
factors. This finding is in line with the fact that PKG1 can di-
rectly phosphorylate CREB (22). By using acute slices, we found
that phosphorylation of CREB by cGMP in striatal neurons
depends on PKG1, suggesting that protein translation of VGAT
at local striatal synapses is unlikely to mediate the transcriptional
regulation by NO signaling. Induction in CREB phosphorylation
can induce transcriptional activation through binding to the CRE
element in target genes (22). In line with this idea, we found
a functional CRE in the VGAT gene and identified a loss in the
phosphorylation level of CREB and in its binding to the VGAT
gene in sGCβ1 KD mice, indicating that CREB positively regu-
lates their transcription. Whether transcriptional regulation of
vesicular neurotransmitter transporters is always coordinated
with that of other presynaptic and vesicular genes is still un-
known. We found that, in contrast to VGAT, only a small subset
of other presynaptic genes were differentially expressed in SPNs
of sGCβ1 KD mice. Previous work in cultured neurons showed
that the transcriptional regulation of VGAT and other vesicular
neurotransmitters transporters is dissociated from that of other
components of the synaptic vesicle (23), and our results in-
dicate that such selective regulation is maintained in the adult
mammalian brain.
The loss of response of neurons transduced with AAV.si.Gucy
to the NO donor diethylamine NONOate confirmed that NO
signaling is impaired in sGC-KD mice. Similar to NO, carbon
monoxide (CO) is another gaseous neurotransmitter and a li-
gand for sGC (24). However, CO affinity to sGC is much lower
than that of NO, and cGMP induction by CO is significantly
lower relative to NO (25). Furthermore, the expression of heme
oxygenase isoforms in the striatum is miniscule whereas basal
cGMP level in the striatum is the highest in the brain. Taken
together, it is likely that the activity of sGC in its role in medi-
ating GABA transmission and plasticity is primarily regulated by
NO. In contrast to sGCβ1 KD, the mechanism underlying the
reduction in GABA signaling in SPN collaterals after pharma-
cologic inhibition of NOS may not depend on transcriptional
regulation, suggesting that multiple mechanisms mediate the
effect of NO on GABA transmission. Several mechanisms have
been proposed in the action of NO on GABA transmission and
plasticity, including some that are independent of sGC (1, 2). To
identify sGC-dependent effects of NO, we down-regulated sGC
in striatal neurons. In line with our previous reports showing that
sGC and cGMP mediate NO signaling in SPNs (6, 12), the down-
regulation of VGAT levels and the impairment in GABA sig-
naling in sGCβ1 KO clearly indicate that sGC plays a major role
in the function of axon collaterals of SPNs. The reduction in
cGMP levels in response to application of NO donor after loss of
sGC in cultured neurons further supports the idea that sGC
is a major target of NO. However, a role for NO that is in-
dependent of sGC in mediating GABA transmission cannot be
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Fig. 6. Coregulation of VGAT and cGMP levels by dopamine. (A) Dopa-
minergic lesion paradigm. Mice received a unilateral injection of either
6-hydroxydopamine (OHDA) or vehicle to the medial forebrain bundle and
daily intraperitoneal injections of benseazide (15 mg/kg) with L-dopa (6 mg/kg,
LD) or saline (sal). (B) VGAT and DARPP-32 immunolabeling in the striatum
after dopaminergic lesion. Representative images from ipsilateral (ipsi.) and
contralateral (cont.) striatum of a mouse treated with 6-hydroxydopamine and
saline. Note in the magnified images that VGAT labeling (shown in yellow in
the image from the contralateral) is reduced in the soma of SPNs of the ipsi-
lateral striatum (appears green). (Scale bar: 20 μm.) (C) Bar graph summary of
ratios of VGAT and DARPP-32 mean pixel values (n = 5–6 mice per group, seven
slices per mouse). Bars represent mean ratios in the ipsilateral striatum as per-
centage of that in the contralateral ± SD. (D) cGMP levels. Bars represent cGMP
level in the ipsilateral striatum normalized to tissue wet weight, as percentage of
the contralateral ± SD (n = 4–5 mice per group). (E) For each treatment group,
the mean cGMP level is plotted against the mean of VGAT labeling ratio.
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completely ruled out. S-nitrosylation of cysteines in multiple
target proteins has long been suggested to mediate synaptic
plasticity at excitatory synapses (26). Interestingly, S-nitrosylation
of gephrin by NO was recently shown to mediate GABA-A re-
ceptor assembly, suggesting that NO may regulate synaptic plas-
ticity at GABAergic synapses independently of sGC (27). It is
therefore possible that L-NAME–mediated inhibition of GABA
signaling was mediated by changes in S-nitrosylation and that sGC-
dependent and independent mechanisms by NO are activated in
a coordinated manner on both sides of the GABAergic synapse to
mediate GABA signaling and synaptic plasticity.
The reduction in VGAT mRNA level in sGCβ1 KD mice
resulted in a parallel reduction in the level of the protein. In-
terestingly, the reduction in VGAT protein level in sGCβ1 KD
mice was found only in local processes of SPNs but not in their
primary projections. Similarly, the reduction in GABA trans-
mission was found specifically at axon collaterals of SPNs, but not
in their primary extrastriatal terminals. Differences in regulation
of the level of VGAT or in its trafficking between these two types
of terminals have not been reported yet, but several mechanisms
may underlay these differences. Cytoskeletal proteins, including
kinesin motors, which mediate trafficking of synaptic content, may
play a role in the function of axon collaterals (28). Among the
members of this protein superfamily, kinesin 2A and 5 were
previously shown to mediate a specific suppression of collateral-
branch extension (29, 30). Interestingly, we identified an up-
regulation in the level of these proteins, as well as down-regulation
in the level of several other kinesin members (Table S1). Still, the
exact function and cellular distribution of each member of the
kinesin protein family in SPNs is not known, and further work will
be necessary to elucidate their function and regulation in axon
collaterals of SPNs.
Materials and Methods
A full description of the materials and methods can be found in SI Materials
and Methods.
Animals. Experiments were performed in accordance with National Insti-
tutes of Health guidelines for the care and use of laboratory animals, and all
procedures were carried out in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals (31), and were
approved by the Animal Care and Use Committees of the Rockefeller
University, the Weill Medical College of Cornell University, and the Fein-
berg School of Medicine, Northwestern University. For viral injections,
7-wk-old mice (or 5-wk-old mice for electrophysiology studies) were
anesthetized with ketamine/xylazine and were bilaterally injected with
1.5 μL of AAV into the dorsal striatum using a mouse atlas-integrated
stereotaxic instrument (Leica). Coordinates were ±2.05 mm, +0.25 mm,
−3.96 mm lateral, anterior, and ventral from bregma according to the
Paxinos and Franklin mouse brain atlas (2001) (32). Unless specified oth-
erwise, assessment of the effect of the AAV was performed at 25 ± 3.2 d
after injections in lysates of striata that were dissected between anterior +
0.38 and 0.00, relative to bregma. All other in vivo studies are described in
SI Materials and Methods.
RNA Isolation, Purification, and Analysis. Striata and brainstems from six Drd1-
bacTRAP mice (CP-73), both males and females, were pooled to isolate RNA.
RNA was isolated as previously shown (10, 11).
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